Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 11, 2021

Aurinia’s Lupkynis improves renal response rates in lupus nephritis trial

Aurinia Pharmaceuticals has reported results from a Phase III AURORA 1 study of Lupkynis in adult lupus nephritis (LN) patients. 

Trial data showed that Lupkynis (voclosporin) plus standard of care (SoC) of mycophenolate mofetil (MMF) and low-dose corticosteroids offered statistically superior complete renal response (CR) rates versus SoC alone at 52 weeks.

Lupkynis is an oral therapy indicated for treating active LN while MMF and corticosteroids are SoC immunosuppressive agents used to treat the disease.

In January this year, the US Food and Drug Administration (FDA) granted approval to Lupkynis plus a background immunosuppressive therapy regimen for active LN patients.

The global, randomised, double-blind, placebo-controlled Phase III AURORA 1 study enrolled 357 subjects. It analysed the efficacy and safety of Lupkynis 23.7mg twice daily along with SoC versus SOC alone in an ethnically and racially diverse population of active LN patients.

The study data showed a statistically superior complete renal response rates of 41% with Lupkynis as against 23% with the control, thereby meeting its primary endpoint.

Lupkynis also showed statistical significance in all pre-specified hierarchical secondary endpoints such as improved time to 50% decrease from baseline in Urinary Protein Excretion Estimation (UPCR) or and time to UPCR less than 0.5mg/mg versus control.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

The treatment was found to be well tolerated and no unexpected safety signals were noted.

Furthermore, serious adverse events were observed in 21% of Lupknyis treated patients versus 21% in the control arm.

Aurinia Pharmaceuticals Research executive vice-president Robert Huizinga said: “It is the culmination of many years of research both within Aurinia and with investigators and patients and we look forward to continuing our research with this important compound, and to sharing longer-term safety and efficacy data from the ongoing AURORA 2 continuation study in the coming months.”

In October last year, Aurinia initiated an open-label exploratory trial to analyse the antiviral effects of voclosporin in kidney transplant recipients (KTRs) with Covid-19.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU